Biokompatibilitätsprobleme bei der Hämodialyse

1990 ◽  
Vol 10 (02) ◽  
pp. 84-91 ◽  
Author(s):  
U. Weber ◽  
J. Lissmann ◽  
R. Bambauer
Keyword(s):  
Side Effects ◽  
Chronic Hemodialysis ◽  
Low Risk ◽  
Dialysis Fluid ◽  
Hemodialysis Treatment ◽  
Number Of Patients ◽  
Artificial Surfaces ◽  
Near Future

ZusammenfassungSeit erstmals Interaktionen von Blut und körperfremden Materialien bei der chronischen Hämodialysebehandlung beobachtet wurden, folgten zahlreiche Untersuchungen, um das Phänomen der Biokompatibilität zu ergründen. Dies hatte zur Folge, daß erhebliche Verbesserungen bei den Membranen, Schlauchsystemen, Geräten und der Behandlung selbst erzielt werden konnten. Im folgenden wird versucht, einen Überblick über die auslösenden Ursachen und die Phänomene, die durch die Interaktion von Blut mit körperfremden Oberflächen verursacht werden, aufzuzeigen.Die Probleme, die bei der Entwicklung biokompatibler Membranen vorhanden sind, scheinen in naher Zukunft noch nicht alle lösbar zu sein. Unsere ganze Sorgfalt muß daher der Hämodialysebehandlung selbst und der Verringerung ihrer möglichen Nebenwirkungen, die z.B. durch Reste von Sterilisationsmitteln, endotoxinhaltige Dialysierflüssigkeiten hervorgerufen werden können, gelten. Besonders im Hinblick darauf, daß die Zahl der Patienten, die Biomaterialien benötigen, rasch zunimmt und diese Patienten länger leben, wodurch sie den Gefahren durch die Biounverträglichkeit der Materialien länger ausgesetzt werden, sind wir alle aufgefordert, unseren Patienten eine risikoarme Hämodialyse zu ermöglichen served in the treatment of chronic hemodialysis, numerous investigations were performed to definite the phenomena of biocompatibility. As a consequence, considerable improvements in membranes, tube systems, equipments and in the treatment itself have been accomplished. The following is an attempt to demonstrate the initiating causes and the phenomena which results from the interaction of blood with artificial surfaces.The problems being encountered in the development of biocompatible membranes are not likely to all be solved in the near future. We must, therefore, concentrate all our efforts on the hemodialysis treatment itself and on the reduction of its possible side-effects which can, for example, be caused by the remnants of sterilizing agents, dialysis fluid containing endotoxin, etc. Especially in view of the fact that the number of patients requiring biomaterials is rapidly increasing and that these patients are living longer, whereby they are exposed to the dangers of bioincompatibility of the materials for a longer period of time, we are all called upon to provide low-risk hemodialysis for our patients.

Safety Management of Dialysis Fluid in Japan: Important Duties and Responsibilities of Clinical Engineers

2021 ◽  
pp. 1-6
Author(s):  
Masanori Shibata
Keyword(s):  
Renal Failure ◽  
Safety Management ◽  
Standard Procedure ◽  
Medical Personnel ◽  
Maintenance Hemodialysis ◽  
Dialysis Fluid ◽  
Fluid Delivery ◽  
Technical Ability ◽  
Number Of Patients ◽  
Clinical Engineers

Dialysis therapy is the predominant choice for renal failure in Japan, and almost 30% of the patients with renal failure have been treated for 10 years or more. Dialysis became the standard procedure to treat renal failure nationwide in the 1980s. However, at that time, managing the increased number of patients on maintenance hemodialysis as well as operating and maintaining the newly developed advanced medical technologies at extensive numbers of clinical sites proved problematic. To help address this, the clinical engineer system was established in 1987 and certain aspects of the clinical engineers’ role remain unique to Japan today. For the last 30 years, clinical engineers have worked as frontline medical personnel not only operating dialysis-related devices but also placing their hands directly on patients when providing care, routinely performing puncture, and administering drugs through the blood circuit under physicians’ instructions. As part of their work, they crucially maintain the use of central dialysis fluid delivery systems (CDDSs) – also unique to Japan – which prepare and deliver a large quantity of dialysis fluid through a central circuit to individual dialysis consoles. CDDSs are widely used because they effectively alleviated the early confusion at clinical sites caused by the rapidly increasing hemodialysis population and the serious shortage in medical personnel. Moreover, clinical engineers alone have the technical ability to provide safe dialysis fluids adjusted to strict standards at clinical sites. In this review article, we focus on the crucial roles that clinical engineers have in maintaining the safety of dialysis-related medical devices and the preparation and delivery of dialysis fluid at many dialysis facilities across the country.

scholarly journals Impact of COVID-19 pandemic on non-COVID patient’s management in urology: a public hospital experience in Mumbai

2021 ◽  
Vol 27 (1) ◽  
Author(s):  
Nikhilesh A. Jibhakate ◽  
Sujata K. Patwardhan ◽  
Ajit S. Sawant ◽  
Hemant R. Pathak ◽  
Bhushan P. Patil ◽  
...  
Keyword(s):  
Tertiary Care ◽  
Stone Disease ◽  
Outpatient Clinics ◽  
Percentage Decrease ◽  
Emergency Procedures ◽  
Number Of Patients ◽  
Long Term Impact ◽  
Tertiary Care Hospitals ◽  
The Impact ◽  
Near Future

Abstract Background To evaluate the impact of COVID-19 lockdown on non-COVID urological patient’s management in tertiary care urology centres. Methods This is an observational study in which data of patients visiting the urology department of all the MCGM run tertiary care hospitals were recorded for the duration of 1 April 2020 to 31 July 2020 and were compared to data of pre-COVID-19 period of similar duration. Results There was a decrease of 93.86% in indoor admissions of urology patients during the COVID-19 lockdown. Indoor admissions for stone disease, haematuria, malignancy accounted for 53.65%, 15.85%, 9.75%, respectively. Elective surgeries had the highest percentage decrease followed by emergency and semi-emergency procedures. There was a reduction of more than 80% in patients attending outpatient clinics. Stone disease and its consequences were the main reasons for visiting outdoor clinics (39%). A substantial number of patients presented with flank and abdominal pain (14.8%) and benign enlargement of the prostate (10.23%). Malignancy accounted for a very small number of patients visiting outdoor clinics (1.58%). Conclusions COVID-19 pandemic has a profound impact on patient care and education in Urology. There was more than ninety percent reduction in indoor admissions, operative procedures, and outpatient clinics attendance. Once the pandemic is controlled, there will be a large number of patients seeking consultation and management for urological conditions and we should be prepared for it. Surgical training of urology residents needs to be compensated in near future. Long-term impact on urological patient outcome remains to be defined.

scholarly journals P1490MONTHLY TREND AND SEASONALITY IN ACUTE AND CHRONIC HEMODIALYSIS; RESULT FROM NATIONWIDE DATABASE OF MEDICAL BILLS OF UNIVERSAL HEALTH CARE INSURANCE SYSTEM IN JAPAN

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Ryoya Tsunoda ◽  
Hirayasu Kai ◽  
Masahide Kondo ◽  
Naohiro Mitsutake ◽  
Kunihiro Yamagata
Keyword(s):  
Health Care ◽  
Seasonal Variation ◽  
Chronic Hemodialysis ◽  
Universal Health Care ◽  
Health Care Insurance ◽  
Individual Data ◽  
Insurance System ◽  
Number Of Patients ◽  
Medical Bills ◽  
Universal Health

Abstract Background and Aims Although knowing the accurate number of patients of hemodialysis important, data collection is a hard task. Establishing a simplified and prompt method of data collection for perspective hemodialysis is strongly needed. In Japan, there is a universal health care insurance system that covers almost all population. This study aimed to know a seasonal variation of hemodialysis patients using the big database of medical bills in Japan. Method Japanese Ministry of Health, Labour and Welfare established a big database named National Database (NDB), that consists of medical bills data in Japan. All bills data were sent to the data server from The Examination and Payment Agency, the organization that receives all medical bills from each medical institution and judge validity for payment. Each record of the database consists of bill data of one patient of a month for each medical institution. All data were anonymized before saved in the server and gave virtual patient identification number (VPID) that is unique for each patient. VPID is a hash value calculated by patient’s individual data such as name, date of birth, so that the value cannot be duplicate. Calculation of VPID is executed by an irreversible way to make it difficult to decrypt VPID into patient’s individual data. This database includes all information about medical care of whole population in Japan except for patients not under the insurance system (patients under public assistance system, victims of the war, or any other specified people under the public medical expense). Using this database, we investigated monthly number of patients who were recorded to be undergone hemodialysis (HD, includes hemodiafiltration). We searched chronic HD patients who have undergone HD on the month and continued it for 3 months, and acute HD patients who have discontinued HD within 3 months. Results In NDB, the number of chronic HD patients under public insurance system who confirmed to have undergone HD in December 2014 was 284 433. In contrast, the number of HD patients identified from the year-end survey by Japanese Society of Dialysis Therapy in the same year was of 311 193, but this number includes patients not under insurance system. Incidence rate of acute HD in Japan was persisted at 30-39 per million per month. There is a reproducible seasonal variation in number of acute HD patients, that increases in every winter and decreasing in every summer. The significantly highest frequency was observed in February(38.5/million/month) compared with September(30.6/million/month), the lowest month of the year (p<0.01). Conclusion We could show the trend in number of HD patients using nationwide bills data. Seasonality in some clinical factors in patients under chronic hemodialysis such as blood pressure, intradialytic body weight gain, morbidity of congestive heart failure, and, mortality, has been reported in many observational studies. Also, there are a few former reports about seasonality in AKI. However, a report about acute RRT is few. From our knowledge, this is the first report that revealed monthly dynamics of HD in a whole nation and rising risk of acute HD in winter. The true mechanism of this seasonality remains unclear. We have to establish a method to collect clinical data such as prevalence of CKD, causative diseases of AKI, kinds of precedent operations, and medications in connection with billing data.

scholarly journals CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario

2019 ◽  
Author(s):  
Satish Sankaran ◽  
Jyoti Bajpai Dikshit ◽  
Chandra Prakash SV ◽  
SE Mallikarjuna ◽  
SP Somashekhar ◽  
...  
Keyword(s):  
High Risk ◽  
Early Stage ◽  
Risk Groups ◽  
Treatment Decisions ◽  
Low Risk ◽  
Not Given ◽  
Breast Cancer Patients ◽  
Number Of Patients ◽  
Risk Of Cancer ◽  
The Impact

AbstractCanAssist Breast (CAB) has thus far been validated on a retrospective cohort of 1123 patients who are mostly Indians. Distant metastasis–free survival (DMFS) of more than 95% was observed with significant separation (P < 0.0001) between low-risk and high-risk groups. In this study, we demonstrate the usefulness of CAB in guiding physicians to assess risk of cancer recurrence and to make informed treatment decisions for patients. Of more than 500 patients who have undergone CAB test, detailed analysis of 455 patients who were treated based on CAB-based risk predictions by more than 140 doctors across India is presented here. Majority of patients tested had node negative, T2, and grade 2 disease. Age and luminal subtypes did not affect the performance of CAB. On comparison with Adjuvant! Online (AOL), CAB categorized twice the number of patients into low risk indicating potential of overtreatment by AOL-based risk categorization. We assessed the impact of CAB testing on treatment decisions for 254 patients and observed that 92% low-risk patients were not given chemotherapy. Overall, we observed that 88% patients were either given or not given chemotherapy based on whether they were stratified as high risk or low risk for distant recurrence respectively. Based on these results, we conclude that CAB has been accepted by physicians to make treatment planning and provides a cost-effective alternative to other similar multigene prognostic tests currently available.

scholarly journals Cefazolin serum concentrations with fixed intravenous dosing in patients on chronic hemodialysis treatment

1999 ◽  
Vol 14 (8) ◽  
pp. 2050-2051 ◽  
Author(s):  
D. Kuypers ◽  
J. Vanwalleghem ◽  
B. Maes ◽  
T. Messiaen ◽  
Y. Vanrenterghem ◽  
...  
Keyword(s):  
Chronic Hemodialysis ◽  
Serum Concentrations ◽  
Hemodialysis Treatment

Chlorpromazine Metabolism in Chronic Schizophrenics

1971 ◽  
Vol 119 (553) ◽  
pp. 589-596 ◽  
Author(s):  
S. Sved ◽  
A. Perales ◽  
D. Palaic
Keyword(s):  
Side Effects ◽  
Chronic Schizophrenics ◽  
Number Of Patients ◽  
Phenothiazine Drugs ◽  
Chlorpromazine Metabolism

At present the phenothiazine drugs constitute the medication of choice in the treatment of schizophrenia. While in most schizophrenics treatment with phenothiazines does ameliorate the symptoms of the disease there are a certain number of patients who remain resistant to therapy. In such patients the side effects caused by phenothiazines may also be less pronounced or completely absent.

Advances in the Management of Parkinsons Disease

1976 ◽  
Vol 21 (3) ◽  
pp. 139-148 ◽  
Author(s):  
C. D. Marsden
Keyword(s):  
Side Effects ◽  
Replacement Therapy ◽  
Term Treatment ◽  
Parkinsons Disease ◽  
Complex Time ◽  
Optimum Dosage ◽  
New Approaches ◽  
Long Term Treatment ◽  
Near Future

The treatment of Parkinson's disease today is complex, time-consuming, but rewarding. The introduction of levodopa has not cured the disease, but has provided the most powerful therapy available yet. Its use is limited by side effects and careful titration to optimum dosage, often in combination with other drugs, is required. Despite best therapy, some patients never respond, and others begin to lose benefit after some years of therapy. New problems, such as the ‘on-off’ effect have appeared with long-term treatment, and require careful adjustment of dosage. As with any replacement therapy, a balance between sub-optimal benefit and side effects has to be discovered and maintained by careful and frequent review. New approaches to treatment may offer further improvement in the near future.

Superficialization of Basilic Vein: Last Chance for a Native Arteriovenous Fistula in Hemodialysis Patients

2003 ◽  
Vol 4 (1) ◽  
pp. 21-24 ◽  
Author(s):  
M. Onaran ◽  
D. Erer ◽  
I. Şen ◽  
E.E. Elnur ◽  
E. Iriz ◽  
...  
Keyword(s):  
Arteriovenous Fistula ◽  
Vascular Access ◽  
Brachial Artery ◽  
Subcutaneous Tissue ◽  
Vascular Grafts ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Basilic Vein ◽  
Number Of Patients

Background Although the best type of vascular access for chronic hemodialysis patients is a native arteriovenous fistula, in an increasing number of patients all the superficial veins have been used and only the placement of vascular grafts or permanent catheters is left. Superficialization of the basilic vein is a possible alternative. Materials and Methods In 49 chronic hemodialysis patients who had no possibilities to have a native arteriovenous fistula created, we performed a basilic vein- brachial artery fistula in the arm. During the same operation the basilic vein was then superficialized for easier access for hemodialysis. Results Mean follow-up was 22.36±15.56 months. Forty-eight patients are still undergoing hemodialysis with their superficialized basilic vein native A-V fistula without any complications. Only one fistula was thrombosed just after the procedure because of poor vessel quality. Conclusion For hemodialysis patients who have no suitable superficial veins at the wrist or elbow, performing a basilic vein - brachial artery fistula and superficializing the vein to the subcutaneous tissue is an acceptable choice before deciding to use more complicated procedures like vascular grafts.

scholarly journals A comparative study to ascertain the efficacy of intravenous dexmedetomidine versus intravenous tramadol to prevent post-operative shivering after laparoscopic surgery

2019 ◽  
Vol 6 (3) ◽  
pp. 713
Author(s):  
Kishore K. ◽  
Syed Ali Aasim ◽  
Manish Kumar J.
Keyword(s):  
Laparoscopic Surgery ◽  
Side Effects ◽  
Comparative Study ◽  
General Anaesthesia ◽  
Power Number ◽  
Group Iii ◽  
Group I ◽  
Number Of Patients ◽  
Envelope Method ◽  
Level Of Significance

Background: Shivering is commonly encountered both after regional and general anaesthesia (GA) with a little higher incidence in patients receiving GA. The aim of study was to compare the effectiveness of dexmedetomidine and tramadol in decreasing postoperative shivering in patients undergoing laparoscopic surgery.Methods: Total 120 patients were included in this study. In order to get a 5% level of significance and 80% power number of patients required in each group was 40, with a total of 120 patients. Randomization of groups was done based on closed envelope method. Patients were allocated into three groups group I, II and III of 40 patients each. Patients in group I and group II were administered 0.75 μg/kg of dexmedetomidine and 1.5 mg /kg of tramadol in 100 ml NS respectively half a before extubation, while patients in group III did not receive any pharmacological intervention.Results: All three groups were comparable regarding distribution of age, gender, ASA grade and temperature at beginning and end of surgery and were non-significant.Conclusions: Dexmedetomidine seems to possess anti-shivering properties and was found to reduce the occurrence of shivering in patients undergoing general anaesthesia with minimal side effects although its anti-shivering effect was not superior to tramadol.

Sign in / Sign up

Export Citation Format

Share Document